{"classes":[{"categories":[{"measurements":[{"comment":"NA = Insufficient number of participants with events. 2 subjects with responses, but only one with an event, Median duration of response could not be estimated as 1 of the 2 subjects response had not had a progression event, therefore the 95% CIs are not estimable. 1 patient remains in response at end of study.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"PR was reported for 1 subject with a progression event therefore no CIs are estimable","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"3.7"},{"comment":"Insufficient number of participants with events. Median duration of response could not be estimated as the 1 subject with PR had not had a progression event.","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"description":"Duration of Response (DoR) includes only patients that have responded with an objective disease response (PR or CR) and is defined as the time from the first tumor assessment that supports the patient's objective disease response to the time of PD or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"300mg DKN-01 monotherapy in recurrent EEC. DKN-01 administered by IV infusion.","id":"OG000","title":"DKN-01 Monotherapy in Recurrent EEC"},{"description":"300mg DKN-01+paclitaxel in recurrent EEC. DKN-01 and paclitaxel administered by IV infusion.","id":"OG001","title":"DKN-01 + Paclitaxel in Recurrent EEC"},{"description":"300mg DKN-01 monotherapy in recurrent EOC. DKN-01 administered by IV infusion.","id":"OG002","title":"DKN-01 Monotherapy in Recurrent EOC"},{"description":"300mg DKN-01+paclitaxel in recurrent EOC. DKN-01 and paclitaxel administered by IV infusion.","id":"OG003","title":"DKN-01 + Paclitaxel in Eecurrent EOC"},{"description":"300mg DKN-01 in carcinosarcoma. DKN-01 administered by IV infusion.","id":"OG004","title":"DKN-01 300mg Monotherapy in Carcinosarcoma"},{"description":"600mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.","id":"OG005","title":"DKN-01 600mg Monotherapy in Carcinosarcoma"},{"description":"300mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.","id":"OG006","title":"DKN-01 300mg + Paclitaxel in Carcinosarcoma"},{"description":"600mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.","id":"OG007","title":"DKN-01 600mg + Paclitaxel in Carcinosarcoma"}],"paramType":"MEDIAN","populationDescription":"Number of participants analyzed only includes the responders in each group.","reportingStatus":"POSTED","timeFrame":"Baseline to study completion (approximately 11 months)","title":"Duration of Response (DoR) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).","type":"SECONDARY","unitOfMeasure":"months"}